In the EVG / COBI/FTC/TDF group through week @ , HIV-@ from @ patients ( @ % ; @/@ treated patients ) developed primary IN strand transfer inhibitor ( INSTI ) ( n = @ ) and/or nucleoside RT inhibitor ( NRTI ) resistance substitutions ( n = @ ) .